The same authors suggested that EVs bearing ICAM1 could be a novel biomarker of ILD progression.[16] Pulmonary functional tests, mainly force vital capacity (FVC%) and diffuse capacity of the lungs for carbon monoxide %, were used for assessing ILD severity, giving divergent results concerning the impact of EVs (Table 1). The gene discussed is ICAM1; the disease is interstitial lung disease.